oncoMonitor™
Molecular test
for detection of cancer progression and treatment monitoring
About us
The Prague-based biotechnological start-up Elphogene has received an initial investment from i&i Prague in order to implement its oncoMonitor™, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.
The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute.
Results & Experiences
We have been investigating ctDNA from patients' blood since 2009. We gained experience with patients with various types of cancer (lungs, pancreas, stomach, head and neck), but we found out the best application for colorectal cancer patients for whom oncoMonitor™ was primarily developed.
So far, in several extensive research studies, we have examined more than 500 such patients for the presence of ctDNA, and in at least 30 of them, we conducted long-term postoperative monitoring of ctDNA levels.
News & Media
AACR Annual Meeting 2025 – Apr 25–30, 2025
The presentation of an Elphogene abstract on the newly discovered phenomenon of resistance to anticancer therapy was featured at the prestigious annual conference.
26th National Conference on DNA Diagnostics – Apr 17–19, 2024
Doc. Minárik’s lecture presented unique results of non-invasive monitoring of cancer treatment.
6th Central-Eastern European Congress on cfDNA – Mar 7–8, 2024
Doc. Marek Minárik presented the oncoMonitor technology at the 6th Central-Eastern European Congress on cfDNA.
Article in the World Journal of Cancer – 2023
Researchers from Elphogene and Genomac, in collaboration with FN Plzeň, published an article in the Journal of Cancer on the relationship between biomarkers and circulating tumor DNA in patients with advanced lung cancer.
Doc. Minárik and the Elphogene team, in collaboration with FN Plzeň, published a study on the use of the oncoMonitor test for long-term monitoring of treatment in non-small cell lung cancer.
13th Annual PragueONCO – Jan 26–28, 2022
Presentation of Elphogene’s oncoMonitor technology for evaluating surgical outcomes and predicting recurrence in lung cancer.
Precision Diagnostics Europe 2021 – May 26–28, 2021
Doc. Minárik presented the development and clinical validation of Elphogene’s oncoMonitor methodology.
Czech biotechnology start-up Elphogene announced a change in its shareholder structure. Marek Minárik, one of the company’s two original founders, is now the sole owner.
The original article describing the clinical implementation of Elphogene’s oncoMonitor® liquid biopsy technology was published in the scientific journal Pathology and Oncology Research (Frontiers Media publishing).
17th Postgraduate SGO Course – Nov 5, 2020
A recording of a short lecture by Doc. Minárik presenting a new generation of tests for screening (not only) colorectal cancer.
Report by CzechSight, s.r.o. - Jun 15, 2020
The report "Detection of cancer recurrence from blood collection is becoming common reality" about Elphogene, s.r.o. published by CzechSight, s.r.o.
